GCGR and metabolic dysfunction-associated steatohepatitis: Other studies show that Cotaduide could intervene and reverse NASH through improving metabolism in the liver including lipid and glucose metabolism via GCGR in mice, suggesting that Cotaduide may be a potential and viable therapeutic as a targeted drug intervention to reverse disease progression of NASH (131).